Human Peripheral Blood Leukopak, Frozen
Primary human cells, frozen

Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
Overview
Each frozen leukopak is a highly concentrated, low-volume apheresis collection from a single, normal donor, using Institutional Review Board (IRB)-approved consent forms and protocols. Each full-sized leukopak is produced from ~2 - 3x blood volumes using the Spectra Optia® Apheresis System, with acid-citrate-dextrose solution A (ACDA) as the anticoagulant. The collected product is then cryopreserved in a controlled-rate freezer. High-resolution HLA typing (Class I and Class II alleles and CMV status) are available upon request. Donor specifications (e.g. BMI category, smoking status, ethnicity, etc.) can be requested in the comment box above, after selecting from the product options. Donors are screened for HIV-1, HIV-2, hepatitis B, and hepatitis C.
Certain products are only available in select territories. Please contact your local sales representative or Product & Scientific Support at techsupport@stemcell.com for further information.
Browse our Frequently Asked Questions (FAQs) on Primary Cells.
Data Figures

Figure 1. Typical Flow Cytometric Analysis Profile of a Leukopak Before Cryopreservation
Representative gating strategy for flow cytometric immunophenotyping of the different cell subpopulations present in a leukopak product prior to cryopreservation. The CD45 plot was gated on viable single cells while all other plots were gated on viable CD45+ single cells. In the above example, the cell frequencies (as a percentage of the overall leukopak product) are as follows: monocytes (CD14+) 19.9%, B cells (CD19+) 13.9%, NK cells (CD3-CD56+) 6.3%, Helper T cells (CD3+CD4+) 28.5%, and Cytotoxic T cells (CD3+CD8+) 13.5%.

Figure 2. Mean Percentages of Cell Subpopulations in a Leukopak
Representative chart showing the average frequencies of major immune subsets in leukopak products, as measured by flow cytometry prior to cryopreservation. Values shown are mean percentages of total viable leukocytes present in a leukopak (n ≥ 30).
Protocols and Documentation
Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.
Applications
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Resources and Publications
Educational Materials (3)
Quality Statement:
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.